Atypical meningioma is a subtype of meningioma that is prone to recurrence and is a WHO grade II non-benign meningioma. However, the prognosis of patients with atypical meningioma varies widely, with some meningiomas remaining stable for a long time after surgical resection and others recurring even after surgical resection with adjuvant radiation therapy. For larger recurrent atypical meningiomas, re-surgical resection is the primary treatment. Many atypical meningiomas have to be surgically removed multiple times due to recurrence. Mr. Wu had his sixth craniotomy. 13 years ago, in his prime, Mr. Wu had his first surgery for a meningioma in his head while he was working in his hometown. However, three years later the tumor recurred and Mr. Wu had to undergo another craniotomy to remove the meningioma, this time with a WHO grade II atypical meningioma pathology diagnosis. In the following time, Mr. Wu’s meningioma was found to have recurred about 2 years later, and he was transferred to major hospitals in Beijing and Shanghai for craniotomy, gamma knife and general radiation therapy, hoping to control the atypical meningioma. However, the atypical meningioma recurred again and again, and the surgery was more difficult than ever to remove it completely. This time, the atypical meningioma had grown from the supratentorial area pressing on the occipital lobe of the brain to the infratentorial area pressing on the cerebellum. Mr. Wu underwent a sixth craniotomy to remove the atypical meningioma that was compressing the cerebellum, and he recovered well after the surgery. However, this atypical meningioma is likely to recur again, and the time interval between recurrences has become shorter and shorter. For this kind of atypical meningioma in the brain that is prone to recurrence, its treatment plan is still mainly craniotomy to remove the atypical meningioma as much as possible in a safe way. However, sometimes atypical meningiomas are difficult to resect completely, and the recurrence of atypical meningiomas can be prolonged by adjuvant radiation therapy after surgery. In contrast, chemotherapy and targeted therapy, which are commonly used in other malignancies, have inaccurate effects. The conventional chemotherapeutic drugs temozolomide, hydroxyurea, vincristine, doxorubicin, cyclophosphamide, and adriamycin have little effect on meningiomas or exhibit serious toxic side effects. The efficacy of drugs that inhibit progesterone receptors or estrogen receptors is also uncertain, and drugs that target vascular, platelet-derived growth factor receptors, and epidermal growth factor receptors are still being confirmed by the results of clinical trials. Even immunotherapy, which is currently held in high regard, needs to be validated by clinical trial results in this recurrent form of atypical meningioma.